We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Shows Promise for Early Detection of Dementia

By LabMedica International staff writers
Posted on 19 Mar 2025
Print article
Image: The blood test could help predict the development of dementia years before symptoms appear (Photo courtesy of 123RF)
Image: The blood test could help predict the development of dementia years before symptoms appear (Photo courtesy of 123RF)

Idiopathic REM sleep behavior disorder (iRBD) causes individuals to physically act out their dreams while sleeping. This disorder is strongly linked to a high risk of developing Parkinson’s disease and a related condition known as Dementia with Lewy Bodies (DLB). DLB is a type of dementia that leads to memory and cognitive decline, as well as vivid visual hallucinations and motor difficulties similar to Parkinson’s. Early detection of dementia risk could significantly influence how doctors manage patient care, allowing them to plan ahead and potentially offer more tailored, effective treatments. Now, a simple blood test could offer the potential to predict dementia development years before symptoms manifest in those with this sleep disorder.

Researchers at McGill University (Quebec, Canada) have found that a blood test initially created to detect Alzheimer’s disease could also help identify which iRBD patients are at higher risk of developing Dementia with Lewy Bodies. This test measures two proteins in the blood that are biomarkers for Alzheimer’s. In the study, the researchers followed 150 iRBD patients, taking annual blood samples to test for the biomarkers and tracking their health over time.

Remarkably, the blood test conducted four years prior successfully predicted dementia in nearly 90% of the patients who eventually developed the condition. Published in the journal Brain, the study also suggests that the early stages of Parkinson’s and Alzheimer’s share more similarities than previously recognized. The research team plans to expand the study to evaluate the test’s ability to predict dementia risk in individuals already diagnosed with Parkinson’s disease and in other groups at risk for Dementia with Lewy Bodies.

"Our findings suggest that Alzheimer’s treatments could also be tested in patients with this sleep disorder. Perhaps, if treatments start early enough, Dementia with Lewy Bodies can be prevented,” said first author Dr. Aline Delva.

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.